JP2014518615A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518615A5
JP2014518615A5 JP2014506600A JP2014506600A JP2014518615A5 JP 2014518615 A5 JP2014518615 A5 JP 2014518615A5 JP 2014506600 A JP2014506600 A JP 2014506600A JP 2014506600 A JP2014506600 A JP 2014506600A JP 2014518615 A5 JP2014518615 A5 JP 2014518615A5
Authority
JP
Japan
Prior art keywords
seq
psma
amino acid
acid sequence
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014506600A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518615A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/034575 external-priority patent/WO2012145714A2/en
Publication of JP2014518615A publication Critical patent/JP2014518615A/ja
Publication of JP2014518615A5 publication Critical patent/JP2014518615A5/ja
Pending legal-status Critical Current

Links

JP2014506600A 2011-04-22 2012-04-20 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法 Pending JP2014518615A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478449P 2011-04-22 2011-04-22
US61/478,449 2011-04-22
PCT/US2012/034575 WO2012145714A2 (en) 2011-04-22 2012-04-20 Prostate-specific membrane antigen binding proteins and related compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017023634A Division JP6585105B2 (ja) 2011-04-22 2017-02-10 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法

Publications (2)

Publication Number Publication Date
JP2014518615A JP2014518615A (ja) 2014-08-07
JP2014518615A5 true JP2014518615A5 (enExample) 2015-05-21

Family

ID=47042195

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014506600A Pending JP2014518615A (ja) 2011-04-22 2012-04-20 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
JP2017023634A Active JP6585105B2 (ja) 2011-04-22 2017-02-10 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
JP2019087888A Pending JP2019165734A (ja) 2011-04-22 2019-05-07 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017023634A Active JP6585105B2 (ja) 2011-04-22 2017-02-10 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
JP2019087888A Pending JP2019165734A (ja) 2011-04-22 2019-05-07 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法

Country Status (15)

Country Link
US (4) US20140161800A1 (enExample)
EP (1) EP2699596A4 (enExample)
JP (3) JP2014518615A (enExample)
CN (1) CN103687872A (enExample)
AU (1) AU2012245260B2 (enExample)
BR (1) BR112013027224A8 (enExample)
CA (1) CA2833019A1 (enExample)
IL (1) IL228991A0 (enExample)
MX (1) MX355908B (enExample)
MY (1) MY171343A (enExample)
RU (1) RU2632647C2 (enExample)
SG (1) SG194510A1 (enExample)
UA (1) UA118950C2 (enExample)
WO (1) WO2012145714A2 (enExample)
ZA (1) ZA201307559B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
KR20150004856A (ko) * 2012-04-20 2015-01-13 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Cd3 결합 폴리펩타이드
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
EP3243837A4 (en) * 2015-01-08 2018-12-05 Kyowa Hakko Kirin Co., Ltd. Bispecific antibody binding to trailr2 and psma
WO2016130819A2 (en) * 2015-02-11 2016-08-18 Emergent Product Development Seattle Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017027422A1 (en) * 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
JP7058219B2 (ja) * 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Cd3及びpsmaに結合するヘテロ二量体抗体
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CA3056261A1 (en) * 2017-04-07 2018-10-11 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US12060427B2 (en) * 2018-03-28 2024-08-13 Mitsubishi Tanabe Pharma Corporat Drug conjugates of cMET monoclonal binding agents, and uses thereof
WO2020047326A2 (en) * 2018-08-31 2020-03-05 ALX Oncology Inc. Decoy polypeptides
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
EP3966250A4 (en) * 2019-05-07 2022-11-23 Immunorizon Ltd. PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTIONS AND METHODS OF USE THEREOF
KR20220044904A (ko) 2019-05-31 2022-04-12 알렉소 온콜로지 인크. 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
JP7665538B2 (ja) 2019-06-14 2025-04-21 テネオバイオ, インコーポレイテッド Cd22及びcd3に結合する多重特異性重鎖抗体
CN114845710A (zh) 2019-11-27 2022-08-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
CN111303288B (zh) * 2020-03-04 2020-12-25 和铂医药(苏州)有限公司 一种分离的结合抗原psma的蛋白及其用途
IL299748A (en) 2020-07-08 2023-03-01 Lava Therapeutics N V Antibodies that bind PSMA and T gamma delta receptors
EP4255574A1 (en) * 2020-12-01 2023-10-11 Aptevo Research and Development LLC Heterodimeric psma and cd3-binding bispecific antibodies
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス,インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
US20240302379A1 (en) * 2020-12-24 2024-09-12 Agency For Science, Technology And Research Methods for identifying and monitoring interactions of protein with ligand
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
TW202317625A (zh) 2021-06-17 2023-05-01 德商百靈佳殷格翰國際股份有限公司 新穎三特異性結合分子
CN113402590B (zh) * 2021-07-14 2022-05-10 呈诺再生医学科技(珠海横琴新区)有限公司 Khl多肽及其在制备tabp-eic细胞中的应用
KR20240049342A (ko) * 2021-08-27 2024-04-16 얀센 바이오테크 인코포레이티드 항-psma 항체 및 이의 용도
EP4466020A4 (en) * 2022-01-21 2026-04-15 Lyvgen Biopharma Holdings Ltd Multi-specific antibodies and their uses in avidity receptor cross-linking and immune modulation
CA3252619A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-CD28 and anti-PSMA antibodies
CA3253777A1 (en) 2022-03-21 2023-09-28 Amgen Inc. Polytherapeutic methods with T-lymphocyte-activating molecules for treating prostate cancer

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
ATE318147T1 (de) 1996-03-25 2006-03-15 Medarex Inc Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
US6150508A (en) 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US6207805B1 (en) * 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7833528B2 (en) 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
NZ517331A (en) 1999-07-29 2004-02-27 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
CN1189483C (zh) 2001-11-23 2005-02-16 上海中信国健药业有限公司 人源化抗cd3单克隆抗体
KR20040077889A (ko) 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (psma)에 대한 인간모노클로날 항체
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2514419A1 (en) 2003-01-28 2004-08-12 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
DK1629011T3 (da) 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
JP4937751B2 (ja) 2003-06-13 2012-05-23 イミューノメディクス、インコーポレイテッド D−アミノ酸ペプチド
EP1638510B1 (en) 2003-07-01 2015-09-02 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
US20050079184A1 (en) 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
ZA200601699B (en) 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
DK1691833T3 (da) 2003-11-28 2010-05-03 Micromet Ag Præparater der omfatter polypeptider
US20050202020A1 (en) 2004-01-09 2005-09-15 Jeffrey Ross Diagnosing and treating cancer
BRPI0507649A (pt) 2004-02-16 2007-07-10 Micromet Ag molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit
WO2005100404A1 (en) 2004-04-19 2005-10-27 Proscan Rx Pharma Prostate cancer diagnosis and treatment
EP2428522A1 (en) * 2004-05-28 2012-03-14 Agensys, Inc. Antibodies that bind to PSCA proteins for diagnosis of cancer
US20070237712A1 (en) 2004-06-14 2007-10-11 Rajasekaran Ayyappan K Methods of Redistributing Apical Target Antigens to Detect and Treat Cellular Proliferative Disease
EA010374B1 (ru) 2004-07-16 2008-08-29 Микромет Аг Полипептиды с повышенной экспрессией
US8066989B2 (en) 2004-11-30 2011-11-29 Trion Pharma Gmbh Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
US20090298195A1 (en) 2005-01-05 2009-12-03 F-Star Biotechnologische Forschungs-Und Entwicklun Gseges M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
CN101160324B (zh) 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
MX2007009878A (es) 2005-02-18 2007-10-03 Medarex Inc Anticuerpos monoclonales para antigeno de membrana especifica para prostata (amep).
ES2417065T3 (es) 2005-04-26 2013-08-05 Trion Pharma Gmbh Combinación de anticuerpos con glucocorticoides para el tratamiento del cáncer
EP1726650A1 (en) 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US7736647B2 (en) * 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
CN103127523A (zh) 2005-06-20 2013-06-05 Psma开发有限公司 Psma抗体-药物缀合物
EP2295080A3 (en) * 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 交差種特異的(cross−species−specific)抗体を含む組成物および該組成物の使用
CN2859269Y (zh) * 2005-11-22 2007-01-17 长沙凯维科技有限公司 一种烟花电点火头
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
DK2177536T3 (da) 2006-03-30 2014-07-14 Glaxo Group Ltd Antistoffer mod amyloid-beta-peptid
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
CA2682605A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2008150485A2 (en) * 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
WO2009017823A2 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
EP2033657A1 (de) 2007-09-04 2009-03-11 Trion Pharma Gmbh Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination
EP2281004A4 (en) 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
JP5380931B2 (ja) * 2008-07-14 2014-01-08 日本ポリウレタン工業株式会社 メチレン架橋ポリフェニルポリイソシアネートの製造方法
EP2727606A3 (en) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
EP4180458A1 (en) * 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Cross-species-specific psma x cd3 bispecific single chain antibody
EP3281955A1 (en) * 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
WO2010042904A2 (en) * 2008-10-10 2010-04-15 Trubion Pharmaceuticals, Inc. Tcr complex immunotherapeutics
EP3243527B1 (en) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
EP2419451A4 (en) 2009-04-14 2012-11-14 Proscan Rx Pharma Inc ANTIBODIES DIRECTED AGAINST THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
EP2241618A1 (en) * 2009-04-14 2010-10-20 Institut Gustave Roussy Prostate cancer cell lines and their use in screening method
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP2448966B1 (en) 2009-07-03 2018-11-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
WO2011075786A1 (en) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究(慕尼黑)有限責任公司 跨物種專一性之PSMAxCD3雙專一性單鏈抗體
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
TWI638833B (zh) 2010-11-30 2018-10-21 中外製藥股份有限公司 細胞傷害誘導治療劑
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US20140056897A1 (en) 2011-03-10 2014-02-27 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
MX348071B (es) 2011-03-16 2017-05-26 Amgen Inc Variantes de fc.
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2525222A1 (en) 2011-05-17 2012-11-21 Markus M. Heiss Initial relative lymphocyte count as predictive biomarker
US9587021B2 (en) 2011-05-21 2017-03-07 Macrogenics, Inc. CD3-binding molecules capable of binding to human and non-human CD3
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
EP3321286B1 (en) 2011-08-23 2021-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
JP6441079B2 (ja) 2011-12-19 2018-12-19 シンイミューン ゲーエムベーハー 二重特異性抗体分子
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
CN108034006A (zh) 2012-01-13 2018-05-15 乌利班-马克西姆利安大学 双抗原诱导的双功能互补作用
US10010623B2 (en) 2012-02-16 2018-07-03 Ucl Business Plc Lysosome-cleavable linker
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
ES2680151T3 (es) 2012-03-01 2018-09-04 Amgen Research (Munich) Gmbh Moléculas de unión de polipéptidos de larga duración
WO2013132268A1 (en) 2012-03-09 2013-09-12 Ucl Business Plc Chemical modification of antibodies
KR20150004856A (ko) 2012-04-20 2015-01-13 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Cd3 결합 폴리펩타이드
KR20150013277A (ko) 2012-05-14 2015-02-04 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US20130309234A1 (en) 2012-05-18 2013-11-21 Trion Pharma Gmbh Correlation of de novo-induced tumor-associated humoral immune responses with improved clinical outcome
ES2924722T3 (es) 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
ES2672974T3 (es) 2012-06-01 2018-06-19 Ibc Pharmaceuticals, Inc. Complejos multiméricos con estabilidad in vivo, farmacocinética y eficacia mejoradas
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
US20140154253A1 (en) 2012-07-13 2014-06-05 Zymeworks Inc. Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
KR20140036905A (ko) 2012-09-18 2014-03-26 삼성전자주식회사 이중특이 항체를 포함하는 단백질 복합체
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
WO2014079000A1 (en) 2012-11-21 2014-05-30 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
US20140377269A1 (en) 2012-12-19 2014-12-25 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
US10329350B2 (en) 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
CA2898100C (en) 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins

Similar Documents

Publication Publication Date Title
JP7499813B2 (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
JP2022177090A5 (enExample)
JP2010533498A5 (enExample)
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
JP7209464B2 (ja) ヒトインターロイキン-2に対する免疫刺激性モノクローナル抗体
JP2019107018A5 (enExample)
JP2014088414A5 (enExample)
RU2016123839A (ru) Новые модуляторы и способы их применения
JP2017535257A5 (enExample)
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
RU2012121875A (ru) Антитела, распознающие содержащий углеводы эпитоп на cd-43 и сеа, экспрессируемых на злокачественных клетках, и способы их применения
CA2793647A1 (en) Prophylaxis of colorectal and gastrointestinal cancer
CA2786479A1 (en) Methods for treating pancreatic cancer
RU2013142600A (ru) Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
JP2018527919A5 (enExample)
RU2012137515A (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
JP2021512614A5 (enExample)
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2018510617A5 (enExample)
JP2021528047A5 (enExample)
JP2007532139A5 (enExample)
JP2012012402A5 (enExample)
JP2012523848A5 (enExample)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
JP2022533538A5 (enExample)